BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 37394414)

  • 21. A novel nomogram and risk classification system predicting the overall survival of patients with papillary renal cell carcinoma after nephrectomy: A population-based study.
    Hu Y; Xu S; Qi Q; Wang X; Meng J; Zhou J; Hao Z; Liang Q; Feng X; Liang C
    Front Public Health; 2022; 10():989566. PubMed ID: 36276376
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma.
    Rosiello G; Larcher A; Fallara G; Giancristofaro C; Martini A; Re C; Cei F; Musso G; Tian Z; Karakiewicz PI; Mottrie A; Bertini R; Salonia A; Necchi A; Raggi D; Briganti A; Montorsi F; Capitanio U
    Urol Oncol; 2022 Jun; 40(6):271.e19-271.e27. PubMed ID: 35140049
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic analysis of postoperative clinically nonmetastatic renal cell carcinoma.
    Shao Y; Xiong S; Sun G; Dou W; Hu X; Yang W; Lia T; Deng S; Wei Q; Zeng H; Li X
    Cancer Med; 2020 Feb; 9(3):959-970. PubMed ID: 31840431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High CLEC-2 expression associates with unfavorable postoperative prognosis of patients with clear cell renal cell carcinoma.
    Xiong Y; Liu L; Xia Y; Wang J; Xi W; Bai Q; Qu Y; Long Q; Xu J; Guo J
    Oncotarget; 2016 Sep; 7(39):63661-63668. PubMed ID: 27564117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathological and genetic markers improve recurrence prognostication with the University of California Los Angeles Integrated Staging System for patients with clear cell renal cell carcinoma.
    Kroeger N; Lebacle C; Hein J; Rao PN; Nejati R; Wei S; Burchardt M; Drakaki A; Strother M; Kutikov A; Uzzo R; Pantuck AJ
    Eur J Cancer; 2022 Jun; 168():68-76. PubMed ID: 35461012
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.
    Correa AF; Jegede O; Haas NB; Flaherty KT; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Dutcher JP; DiPaola RS; Carducci MA; Uzzo RG
    J Clin Oncol; 2019 Aug; 37(23):2062-2071. PubMed ID: 31216227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GRade, Age, Nodes, and Tumor (GRANT) compared with Leibovich score to predict survival in localized renal cell carcinoma: A nationwide study.
    Juul S; Donskov F; Clark PE; Lund L; Azawi NH
    Int J Urol; 2022 Jul; 29(7):641-645. PubMed ID: 35362146
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interleukin-11 receptor predicts post-operative clinical outcome in patients with early-stage clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Zhu Y; Xu J; Gu J
    Jpn J Clin Oncol; 2015 Feb; 45(2):202-9. PubMed ID: 25420690
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical utility of the Glasgow Prognostic Score in patients undergoing curative nephrectomy for renal clear cell cancer: basis of new prognostic scoring systems.
    Lamb GW; Aitchison M; Ramsey S; Housley SL; McMillan DC
    Br J Cancer; 2012 Jan; 106(2):279-83. PubMed ID: 22166802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High CENPA expression in papillary renal cell carcinoma tissues is associated with poor prognosis.
    Li J; Li Q; Yuan Y; Xie Y; Zhang Y; Zhang R
    BMC Urol; 2022 Sep; 22(1):157. PubMed ID: 36163007
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Architectural Patterns are a Relevant Morphologic Grading System for Clear Cell Renal Cell Carcinoma Prognosis Assessment: Comparisons With WHO/ISUP Grade and Integrated Staging Systems.
    Verine J; Colin D; Nheb M; Prapotnich D; Ploussard G; Cathelineau X; Desgrandchamps F; Mongiat-Artus P; Feugeas JP
    Am J Surg Pathol; 2018 Apr; 42(4):423-441. PubMed ID: 29356723
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identifying biomarkers of papillary renal cell carcinoma associated with pathological stage by weighted gene co-expression network analysis.
    He Z; Sun M; Ke Y; Lin R; Xiao Y; Zhou S; Zhao H; Wang Y; Zhou F; Zhou Y
    Oncotarget; 2017 Apr; 8(17):27904-27914. PubMed ID: 28427189
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genome-wide mutation profiling and related risk signature for prognosis of papillary renal cell carcinoma.
    Zhang C; Zheng Y; Li X; Hu X; Qi F; Luo J
    Ann Transl Med; 2019 Sep; 7(18):427. PubMed ID: 31700863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.
    Wang Y; Yan K; Lin J; Wang J; Zheng Z; Li X; Hua Z; Bu Y; Shi J; Sun S; Li X; Liu Y; Bi J
    Aging (Albany NY); 2020 Nov; 12(21):21854-21873. PubMed ID: 33154194
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
    Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
    Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Preoperative Anemia as an Independent Prognostic Indicator of Papillary Renal Cell Carcinoma.
    Huang J; Feldman AS; Dong L; Cornejo K; Liu Q; Dahl DM; Wu S; Blute ML; Huang Y; Wu CL
    Clin Genitourin Cancer; 2015 Oct; 13(5):e353-60. PubMed ID: 25998556
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Morphological subtyping of papillary renal cell carcinoma: clinicopathological characteristics and prognosis.
    Yamashita S; Ioritani N; Oikawa K; Aizawa M; Endoh M; Arai Y
    Int J Urol; 2007 Aug; 14(8):679-83. PubMed ID: 17681054
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
    Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
    Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oncological outcomes of papillary
    Cetin T; Celik S; Sozen S; Akdogan B; Izol V; Aslan G; Suer E; Bayazit Y; Karakoyunlu N; Ozen H; Baltaci S; Gokalp F; Tinay I
    Arch Ital Urol Androl; 2023 May; 95(2):11218. PubMed ID: 37254924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.